A key to Interpath’s success is their commitment to research and development. Over the past 6 years this research has led the company to discover the new active for which provisional patents have been filed. The active has been proven in-vitro and in-vivo to reduce pain and inflammation, stimulate proteoglycan synthesis, reduce GAG leaching and stimulate chondrocyte proliferation.
In response to these results, Interpath is expanding their research programme on Epiitalis™ in human and animal (canine, feline and equine) studies. This new discovery has the potential to revolutionise the current global joint health treatment market. The company is using state of the art technology and globally sourced expertise to assist in the isolation and definition of the active compound/s. Interpath will adopt innovative presentation forums such as nanotechnology to facilitate maximum penetration to the target sites guaranteeing maximum efficacy.
A pharmaceutical development programme is also being conducted in parallel to the nutraceutical programme with potential to develop Biological Response Modifying (BRM) Osteoarthritis Drugs for human and animal use. Interpath now looks to expand on its success to date with the introduction of quality products that complement and significantly improve upon the existing range.
Interpath has become the Australasian leader in its field and in recent years has established a significant presence internationally. Interpath’s commitment to scientific excellence is being highlighted with presentations of important new research findings at the world’s two most prestigious equine veterinary conferences: the 2008 British Equine Veterinary Association (BEVA) Conference and the 2008 American Association of Equine Practitioners Annual Convention (AAEP).